GENE-BOOST Gene therapy Enhancement through Novel Engineering in Biomanufacturing On Sustainable Technologies
- Coordinator
- Association Genethon, France
- Runs
- 1 October 2026 to 30 September 2030
- Status
- Running
- EU funding
- €6.6m
- Total cost
- —
- Partners
- 10 organisations in 7 countries
- Type
- Innovation Action
- Grant agreement
- 101288700
What the project is doing
In the project's own words, from its summary on CORDIS.
AAV-based gene therapies are promising strategies for patients with life-threatening genetic disorders by restoring gene function in along-term effect reversing disease state. The domain of gene therapy is still facing development challenges at the source of extremelyhigh costs of these drugs on the market today, representing several million euros/dollars per dose, which still highly limits patientaccess to these therapies.
This project aims at developing novel tools for second generation processes enabling a significant impact on the development andmonitoring of gene therapy manufacturing processes. The new tools should help to raise productivity by a factor of 100 compared tofirst generation processes that enabled current clinical trials. The ambition of the project relies on combining different expertise to provide innovative process and analytical technologies for themajor critical parameters that influence the production of viral particles and eventually of AAV vectors, previously identified by theconsortium.
A part of the project will be dedicated to the improvement of the upstream part of the process. Development of next generationsolutions to monitor and improve cell culture conditions will allow a deep characterization of cell culture parameters with theobjective of being able to control and to adapt the parameters during the process. Another major challenge in AAV based gene therapy manufacturing is the purification steps to ensure product quality and safety.
Optimizing the purification steps of the DSP will be also a big improvement in the field, with major outputs such as time and costreduction. Eventually, data collected from all monitored parameters for the DSP will feed a digital twin for comprehensive modeling to predictand optimize bioprocess performance, better monitor operations and facilitate decision making.
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Association Genethon | Evry | France | Coordinator |
| Levacells | Brussels | Belgium | Participant |
| Vsb - Technical University of Ostrava | Ostrava Poruba | Czechia | Participant |
| Sartorius Stedim Biotech GmbH | Gottingen | Germany | Participant |
| future8 gGmbH | St. Ingbert | Germany | Participant |
| Lomartov SL | Burjassot | Spain | Participant |
| Commissariat a L Energie Atomique Et Aux Energies Alternatives | Paris | France | Participant |
| Thales Services Numeriques SAS | Velizy Villacoublay | France | Participant |
| Nova Id Fct - Associacao Para a Inovacao E Desenvolvimento Da Fct | Caparica | Portugal | Participant |
| Sartorius Bia Separations, Separacijske Tehnologije, D.o.o. | Ajdovscina | Slovenia | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI